Autoimmune disease oral lichen planus
The aim of this Cochrane review was to assess the effectiveness and safety of interventions to treat symptomatic, biopsy-proven oral lichen planus (OLP). OLP is a common chronic autoimmune disease associated with cell-mediated immunological dysfunction. The prevalence has been reported as 1.27% and it is more frequently seen in women aged between 30 and 60 years. There are a variety of clinical presentations reticular, papular, plaque, atrophic and ulcerative (erosive), with reticular being the most common.
The Cochrane Oral Health Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) Medline and Embase databases were searched with no restrictions regarding language or date of publication. Bibliographies of identified publications were also checked for relevant studies, and authors were contacted to identify missing and unreported trials. Randomised controlled clinical trials (RCTs) of therapy for symptomatic OLP which compared treatment with a placebo or between treatments or no intervention were considered for this review. 28 trials were included the review with pain being the primary outcomes as it is the indication for treatment of OLP.
You might also like
Autoimmune diseases like lupus orby newlykinked
Rheumatoid arthritis can be accompanied by another autoimmune disease called Sjogren's syndrome. Among other nasty things, it causes severe dry eyes, mouth, vag.
Sjogren's can occur on it's own, but is far more likely to accompany lupus or RA. If she doesn't have those, it is unlikely she has Sjogren's.
I had a big issue with dryness during pregnancy.
Bleeding during sex and severe bleeding during periods is something she should take up with her doctor. Good thing she's having regular visits with her ob/gyn.
Use of curcuminoids in a cohort of patients with oral lichen planus, an autoimmune disease.(Report): An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
Book (Urban & Fischer Verlag)
ImmuPharma extends research ties in France; files for patents on new peptide — Proactive Investors UK
.. the success ImmuPharma has already demonstrated with our patented peptide for Lupuzor,” said the company's chief scientific officer Dr Robert Zimmer. Lupuzor, for the autoimmune disease lupus, is a phase III-ready drug with blockbuster potential.
Clinical Dermatology (Clinical Dermatology (Habif))
Pathology of the Skin
eBooks (Mosby Ltd.)